Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 11-20 of 152 for Ovarian

Edit search filters
  1. A Study of Adding AMG 479 to First Line Chemotherapy in Patients with Optimally Debulked Epithelial Ovarian Cancer

    Rochester, MN

  2. Study of SC-003 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

    Rochester, MN

  3. Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

    Rochester, MN

  4. A Study to Compare Two Surgical Procedures in Women With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

    Rochester, MN

  5. OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

    Rochester, MN, Scottsdale/Phoenix, AZ

  6. MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer

    Rochester, MN

  7. A Study to Evaluate AVB-S6-500 with Paclitaxel vs Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer

    Rochester, MN

  8. A Study for Women who have Platinum Resistant Ovarian Cancer to Evaluate EC145 Combined with Pegylated Liposomal Doxorubicin, Compared to Pegylated Liposomal Doxorubicin Alone

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. A Study of Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer

    Rochester, MN

  10. A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

    Rochester, MN

.

Mayo Clinic Footer